Compare IDEXX Laboratories, Inc. (IDXX) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Levi Strauss & Co. — how do they compare? IDEXX Laboratories, Inc. trades at $519.51 (market cap $40.43B), while Levi Strauss & Co. trades at $18.64 (market cap $7.31B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.5× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 3.36% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Levi Strauss & Co. for 70 Days on average.
| IDXX | LEVI | |
|---|---|---|
Market Cap | $40.43B | $7.31B |
Volume | 692,164 | 13,683,095 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $25.53 |
52-Week Low | $504.70 | $17.92 |
Typical Hold Time | 46 Days | 70 Days |
Enterprise Value | $41.32B | $8.86B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Levi Strauss (LEVI) trades at $19.51, down 4.97% on the day, with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 62.81% gross margins and 8.83% net income margin, supported by four consecutive quarterly earnings beats. Analyst consensus remains strongly bullish with a $29 price target representing 49% upside potential. Recent developments include the appointment of a new CFO and continued momentum in denim demand driving revenue growth.
The stock presents a compelling value opportunity with attractive valuation multiples (P/E 12.53, P/S 1.12) and strong cash flow generation. However, near-term technical weakness and recent cybersecurity concerns require monitoring. The company's direct-to-consumer strategy and international expansion provide growth catalysts, though execution risks and market volatility remain considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
